Compare Fulford India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs VENUS REMEDIES - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA VENUS REMEDIES FULFORD INDIA/
VENUS REMEDIES
 
P/E (TTM) x 398.8 -14.9 - View Chart
P/BV x 6.2 1.0 623.9% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 FULFORD INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
VENUS REMEDIES
Mar-18
FULFORD INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs942126 748.2%   
Low Rs45061 736.5%   
Sales per share (Unadj.) Rs691.4301.8 229.1%  
Earnings per share (Unadj.) Rs11.5-24.9 -46.1%  
Cash flow per share (Unadj.) Rs15.42.5 603.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs380.0293.3 129.6%  
Shares outstanding (eoy) m3.9012.34 31.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.00.3 324.9%   
Avg P/E ratio x60.7-3.8 -1,615.2%  
P/CF ratio (eoy) x45.336.7 123.3%  
Price / Book Value ratio x1.80.3 574.5%  
Dividend payout %17.40-   
Avg Mkt Cap Rs m2,7141,154 235.3%   
No. of employees `0000.40.9 48.0%   
Total wages/salary Rs m505393 128.5%   
Avg. sales/employee Rs Th6,073.04,026.1 150.8%   
Avg. wages/employee Rs Th1,137.4425.0 267.6%   
Avg. net profit/employee Rs Th100.7-331.8 -30.3%   
INCOME DATA
Net Sales Rs m2,6963,724 72.4%  
Other income Rs m12523 557.3%   
Total revenues Rs m2,8223,747 75.3%   
Gross profit Rs m-46395 -11.8%  
Depreciation Rs m15338 4.5%   
Interest Rs m10354 2.7%   
Profit before tax Rs m54-275 -19.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1032 30.4%   
Profit after tax Rs m45-307 -14.6%  
Gross profit margin %-1.710.6 -16.2%  
Effective tax rate %17.7-11.5 -154.0%   
Net profit margin %1.7-8.2 -20.1%  
BALANCE SHEET DATA
Current assets Rs m1,7382,638 65.9%   
Current liabilities Rs m5452,305 23.6%   
Net working cap to sales %44.38.9 495.0%  
Current ratio x3.21.1 278.8%  
Inventory Days Days48135 35.8%  
Debtors Days Days446 9.3%  
Net fixed assets Rs m124,871 0.2%   
Share capital Rs m39123 31.6%   
"Free" reserves Rs m1,4433,496 41.3%   
Net worth Rs m1,4823,619 40.9%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m2,0777,509 27.7%  
Interest coverage x6.70.2 3,011.9%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.5 261.8%   
Return on assets %2.60.6 413.4%  
Return on equity %3.0-8.5 -35.6%  
Return on capital %4.31.6 272.1%  
Exports to sales %00-   
Imports to sales %24.513.9 176.3%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659517 127.6%   
Fx inflow Rs m170-   
Fx outflow Rs m673517 130.3%   
Net fx Rs m-656-517 127.0%   
CASH FLOW
From Operations Rs m90514 17.5%  
From Investments Rs m105-123 -85.0%  
From Financial Activity Rs m-14-387 3.6%  
Net Cashflow Rs m1814 4,297.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 0.2 2,111.1%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 66.4 31.9%  
Shareholders   4,783 20,121 23.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare FULFORD INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA - CADILA HEALTHCARE COMPARISON

COMPARE FULFORD INDIA WITH

MARKET STATS